Results 1 to 10 of about 134,036 (314)
Angiotensin receptor blockers in heart failure after the ELITE II trial [PDF]
Current Controlled Trials in Cardiovascular Medicine, 2000 Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi) for the treatment of heart failure.
Willenheimer Ronnie
doaj +3 more sources
Angiotensin Receptor Blockers [PDF]
High Blood Pressure & Cardiovascular Prevention, 2003 Angiotensin receptor blockers (also known as ARBs) are a class of medications that are widely used by patients with high blood pressure, kidney disease, and heart failure. This article provides information for patients who receive this type of medication.
M Ruilope, Massimo Volpe
openaire +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Pharmacy fill data are a practical tool for assessing medication nonadherence. However, previous studies have not compared the accuracy of pharmacy fill data to measurement of plasma drug levels, or chemical adherence testing (CAT).
David Osula +9 more
doaj +1 more source
Angiotensin Ii Receptor Blockers [PDF]
Baylor University Medical Center Proceedings, 2003 The ARBs have very similar clinical profiles. They do, however, have different pharmacokinetic profiles, which may lead to some differences in efficacy. The newer agents irbesartan, candesartan, telmisartan, and olmesartan have longer half-lives and durations of action than the older agents losartan and valsartan (5).
Amy, Barreras, Cheryle, Gurk-Turner
openaire +2 more sources
Angiotensin receptor blocker neprilysin inhibitors
World Journal of Cardiology, 2021 Heart failure (HF) is a clinical syndrome that results from a structural or functional cardiac disorder that reduces the ability of the ventricle of the heart to fill with, or eject, blood. It is a multifaceted clinical condition that affects up to 2% of the population in the developed world, and is linked to significant morbidity and mortality; it is ...
Usuda, Daisuke +18 more
openaire +2 more sources
Nepalese Medical Journal, 2020 Angiotensin-converting enzyme-2 receptor has been unearthed as a prime site of entry of Severe Acute Respiratory Syndrome Coronavirus 2 owing to its strong affinity towards spike protein of Severe Acute Respiratory Syndrome Coronavirus 2, resulting in ...
Kunal Bikram Shaha +5 more
doaj +1 more source
Current and future use of angiotensin II receptor blockers in patients with COVID-19
Качественная клиническая практика, 2020 No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within ...
A. V. Matveev +2 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundLeft ventricular (LV) remodeling consists in maladaptive changes in cardiac geometry and function following an insult such as ST-segment elevation myocardial infarction (STEMI).
Oriol Iborra-Egea +15 more
doaj +1 more source
Angiotensin receptor blockers (ARBs) [PDF]
Canadian Medical Association Journal, 2011 Guertin and colleagues describe potential savings from restricting use of ARBs in Canada.[1][1] The US Department of Veterans Affairs prefers angiotensin-converting-enzyme (ACE) inhibitors over ARBs, with national criteria for use to guide prescribing.
W. F. Gellad, C. B. Good
openaire +1 more source
The Journal of Clinical Hypertension, 2021 Angiotensin‐receptor blockers are often considered insufficiently efficacious in reducing blood pressure. However, newer angiotensin‐receptor blockers may be more effective than the older ones.
Ji‐Guang Wang +6 more
doaj +1 more source